Document is current
Any future updates will be listed below
-
Authors
Nakitanda, Aya Olivia
Pazzagli, Laura
Pasternak, Björn
Odsbu, Ingvild
-
Funding
Funding for this research was provided by:
Karolinska Institute
- License Information
-
More Information
Article History
Received: 20 May 2024
Accepted: 19 May 2025
First Online: 19 June 2025
Declarations
:
: Ethical approval was obtained from the Regional Ethics Committee in Stockholm (Dnr: 2015/1826-31/2 with amendments 2017/2238-32, 2018/1790-32, 2018/2211-32). Consent for inclusion in the Swedish national registers and participation in register-based studies was waived in accordance with the Swedish Act on ethical review of research relating to humans. The study was conducted in accordance with the Declaration of Helsinki.
: Not applicable.
: AON is an employee of the Centre for Pharmacoepidemiology at Karolinska Institutet which receives funding from different entities including regulatory authorities, pharmaceutical companies and contract research organizations to conduct drug safety and drug utilization studies, unrelated to this work. The other authors report no conflicts of interest in connection with this article.
